Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

BIOCON's revenue is projected to decrease from last year, a development that could lead investors to adopt a more cautious approach. A revenue decline can negatively affect profitability, signaling challenges for the company and making it less attractive for those seeking solid financial performance.

Financial Ratios:

currentRatio 0.00000
forwardPE 34.06562
debtToEquity 66.25900
earningsGrowth -0.95300
revenueGrowth 0.14800
grossMargins 0.60433
operatingMargins 0.07456
trailingEps 3.20000
forwardEps 9.92000

Biocon Limited's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
Biocon Limited's negative gross and operating margins indicate that the company is not generating profit from either production or day-to-day operations. This could suggest cost overruns or declining revenue, impacting its financial stability.
Biocon Limited's forward EPS surpasses its trailing EPS, reflecting expectations of higher profitability in the current year. This suggests that Biocon Limited is projected to generate stronger earnings, indicating an optimistic financial outlook compared to the prior year's results.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

The price of BIOCON has regularly been close to the lower end of projections, suggesting that it might be struggling to meet market expectations. This trend raises questions about the company's future performance.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


BIOCON has been receiving a buy bias from analysts, signaling strong confidence in the stock's future performance. This positive outlook might drive investors to view BIOCON as an attractive option for their portfolios, positioning the company as a stable and profitable investment choice.